Summit Day Two Agenda
8:25 am Chair Opening Remarks
The Patient Perspective
8:30 am The Importance of Demonstrating & Communicating Value of Your Drug Candidate
Synopsis
- Debating how we present a case for reimbursement on life-limiting versus life-threatening disease
- Considering a multistakeholder perspective when communicating the value of your product
- Debating at which stage of drug development to begin thinking about/integrating the patient perspective
- Exploring quality of life surveys in clinical trials
- Patient-reported Outcomes: how do they vary between diseases?
9:00 am Presentation brought to you by OM1
9:30 am What’s Next for Psoriasis? Possible Approaches Toward Cure
Synopsis
- Quickly reviewing current treatments for psoriasis, which all are dependent uponcontinuous dosing to maintain efficacy
- Outlining recent and ongoing treatment strategies for psoriasis that offer the possibility of remission/cure (no disease, off drug)
- Exploring future therapeutic strategies for psoriasis that aim to induce remission/cure
10:00 am Shifting the Alopecia Areata Drug Development Paradigm
Synopsis
- Exploring how psoriasis drug development has shaped the path for alopecia, and how this isn’t fit for purpose
- Maximizing the standard of care for patients through patient-reported outcome standardization
- Moving beyond JAKs: detailing why alopecia needs biologics
10:30 am Clinical Trial Takeaways in the Microbiome Space
11:00 am Morning Break & Structured Networking
Track A: IL-4, IL-13, & IL-31 Associated Diseases
Innovating Delivery Approaches
11:30 am Revolutionizing Oral Drug Development in Atopic Dermatitis
Synopsis
- Championing the specificity of the CCR4 target in atopic dermatitis
- Delivering an orally administered small molecule with efficacious potency
- Validating phase 1 studies with transcriptomic biomarker analyses to enable phase 2 progression
12:00 pm Presentation brought to you by Contract Pharmaceuticals
12:10 pm Delineating the role of IL-31 in the pathophysiology of Prurigo Nodularis
Synopsis
- Shining light on the molecular and cellular characterization of PN
- Scientifically rationalizing the investigation of IL-31 in PN
- Highlighting the mechanism of action of the anti-IL-31RA drug, nemolizumab in PN using a multi-omics approach
Track B: IL-17 Associated Diseases & Rare Skin Disease
Innovating Delivery Approaches
11:30 am Overcoming the Moderate Efficacy Conundrum in PDE4 Inhibition through Hidradenitis Suppurativa
Synopsis
- Outlining PDE4i mode of action and the therapeutic potential to treat across numerous indications with serious unmet need
- Identifying subtypes to target B & D specificity in candidate compound
- Championing an oral delivery method with a good safety profile drug candidate
12:00 pm Presentation brought to you by Nuvisan
12:10 pm A Novel Drug Candidate for Alopecia Areata: An Anti-BTLA Modulator
Synopsis
- Detailing the mode of action for checkpoint inhibitor modulation in chronic inflammatory dermatological disease
- Cataloguing the dermatological diseases to approach with checkpoint inhibitor modulation
- Considering endpoints: pharmacodynamics, moving trials beyond 16 weeks (how to know if we have truly reset the immune system), and psycho/social aspects of a life-limiting disease